ACACA and fatty liver disease: This finding was replicated here in the MPCC model, where multiple ACC1/2 inhibitors were able to both prevent, and reverse hepatic steatosis induced by FFA, with the computed EC50 of Firsocostat being similar to those obtained in a previously published study using a 3D-culture model of NAFLD22.